CAS
PRAX icon

CTC Alternative Strategies’s Praxis Precision Medicines PRAX Stock Holding History

CTC Alternative Strategies’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-925
Closed -$298K – 134
2026
Q1 		$298K Buy
+925
New +$286K 0.68% 54

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CTC Alternative Strategies's PRAX Position: Q2 2026 in Review

CTC Alternative Strategies sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 925 shares — an estimated $298K sold.

CTC Alternative Strategies first reported a position in PRAX in Q1 2026 and held it in 1 quarter. The position peaked at $298K in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • CTC Alternative Strategies reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
  • CTC Alternative Strategies sold 925 Praxis Precision Medicines shares in Q2 2026, an estimated $298K.
  • CTC Alternative Strategies first reported a position in Praxis Precision Medicines in Q1 2026 and held it in 1 quarter.
  • CTC Alternative Strategies's Praxis Precision Medicines position peaked at $298K in Q1 2026.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.